

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Genscript Biotech Corporation**

**金斯瑞生物科技股份有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1548)**

## **VOLUNTARY ANNOUNCEMENT**

### **EXTENSION OF BSJ CONDITIONS FULFILLMENT DATE IN RELATION TO THE BSJ CAPITAL INCREASE AGREEMENT**

Reference is made to the announcement of Genscript Biotech Corporation (the “**Company**”) dated 28 June 2017 (the “**Announcement**”) in relation to, among other things, the BSJ Capital Increase Agreement. Unless otherwise defined, all capitalized terms used herein shall have the same meanings as defined in the Announcement.

Pursuant to the BSJ Capital Increase Agreement, the PRC Fund conditionally agreed to make a capital injection for the increased registered capital of BSJ Nanjing. Upon the BSJ Completion, the equity interest of BSJ HK in BSJ Nanjing will be diluted to 92.590%, and BSJ Nanjing will become an indirect non-wholly owned subsidiary of the Company.

As disclosed in the Announcement, the BSJ Completion is conditional upon the fulfillment or waiver (as the case may be) of the conditions precedent as set out under the BSJ Capital Increase Agreement on or before 31 August 2017 or such later date as the parties to the BSJ Capital Increase Agreement may agree in writing (the “**BSJ Conditions Fulfillment Date**”).

As additional time is required for the fulfillment of certain conditions precedent, including “filing for modification registration with the relevant industrial and commercial authority and obtaining a new business license reflecting the BSJ Capital Increase”, on 13 September 2017, BSJ Nanjing, the PRC Fund, and BSJ Hong Kong entered into a supplemental agreement for the purpose of extending the BSJ Conditions Fulfillment Date to 30 November 2017 (or such later date as the parties to the BSJ Capital Increase Agreement may agree in writing).

Save and except for the aforesaid extension of the BSJ Conditions Fulfillment Date, all other terms of the BSJ Capital Increase Agreement remain unchanged and in full force and effect.

By Order of the Board  
**Genscript Biotech Corporation**  
**Dr. Zhang Fangliang**  
*Chairman*

Hong Kong, 13 September 2017

*As at the date of this announcement, our executive Directors are Dr. ZHANG Fangliang, Ms. WANG Ye and Mr. MENG Jiange; our non-executive Directors are Dr. WANG Luquan, Mr. HUANG Zuie-Chin and Mr. PAN Yuexin; and our independent non-executive Directors are Mr. GUO Hongxin, Mr. DAI Zumian and Ms. ZHANG Min.*

*\* for identification purposes only*